Growth stocks, especially in the biotech sector, often have the potential to deliver outsized returns. A breakthrough in ...

As pharmaceutical giants face a staggering patent cliff, they are aggressively hunting for late-stage assets with clear, high-signal registration pathways [3]. In 2026, the market isn't buying ...

The discussion of local tech’s decline has been brewing for years, but the global AI boom (and biotech’s recent dip) has ...

Shares Biotechnology ETF (IBB) is a BUY: large-cap biotech stability, M&A and AI catalysts, and 2026 upside. Read the full analysis here.

Fast-forward to 2026, and we’ve already seen a handful of U.S. biotechs line up to squeeze through a gradually reopening IPO ...

A new technology elucidated yesterday in the journal Nature has the potential to be a leap forward in DNA synthesis, allowing ...

We’re hoping to see more early-stage funding in 2026 to help newer companies get off the ground. The public market, especially IPOs, has been a bit slow, with only 11 companies going public in 2025, ...

Cuba is keen to deepen its economic engagement with India across sectors such as agro-industry, biotechnology, healthcare, ...

The Colorado Bureau of Investigation (CBI) has completed its comprehensive case review into the 2005 death of author and ...

The Colorado Bureau of Investigation has affirmed that the 2005 death of author and journalist Dr. Hunter S. Thompson was a suicide, following a “comprehensive case review.” ...

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing ...

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on ...